Table of Contents 2
List of Tables 5
List of Figures 6
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2004 to YTD 2010 7
Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2004 to YTD 2010 8
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2004 to YTD 2010 9
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2004 to YTD 2010 10
Merck KGaA, Pharmaceuticals & Healthcare, Medical Devices Deals, 2004 to YTD 2010 11
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 12
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 13
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 14
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 15
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 16
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 17
Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2004 to YTD 2010 18
Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 20
Private Equity 20
Clayton, Dubilier & Rice Acquires VWR International 20
Licensing Agreements 21
Merck Eprova Enters Into Licensing Agreement With Isofol Medical 21
King Pharmaceuticals Enters Into A Licensing Agreement With Merck Sante 22
BioWa Enters Into Licensing Agreement With Merck 23
PDS Biotechnology Enters Into Licensing Agreement With Merck Eprova 24
EMD Serono Enters Into An Agreement With Theratechnologies 25
Idera Pharmaceutical Enters Into Licensing Agreement With Merck 26
Merck Signs An Agreement With Sol-Gel Techologies 27
Merck Expands Licensing Agreement With Biomira 28
Merck Enters Into A Licensing Agreement With Abbott 29
Merck Enters Into An Agreement With Glenmark Pharmaceuticals 30
Dyax Enters Into Licensing Agreement With Serono 31
ImClone Systems Amends Development And License Agreement With Merck 32
Spectrum Pharmaceuticals Enters Into Licensing Agreement With Merck Eprova 33
Merck Expands Licensing Agreement With Biomira 34
Merck KGaA Enters Into License Agreement With Dyax 35
Merck Enters Into Licensing Agreement With Taiho Pharmaceutical 36
Merck Enters Into A Licensing Agreement With Organon BioSciences 37
Merck Enters Into Agreement With Peregrine 38
Eli Lilly Enters Into Licensing Agreement With Merck 39
Merck Enters Into An Agreement With Genaissance Pharmaceuticals 40
Partnerships 41
Cancer Research And Cancer Research Technology Enters Into An Agreement With Merck 41
EMD Serono Enters Into Collaboration Agreement With Brigham and Women’s Hospital 42
EMD Chemicals Enters Into Co-Development Agreement With MitoSciences 43
EMD Serono Enters Into Agreement With M. D. Anderson Cancer Center 44
Fast Forward Enters Into Worldwide Agreement With EMD Serono 45
EMD Serono Enters Into Co-Promotion Agreement With Emmaus Medical 46
caprotec bioanalytics Enters Into Collaboration Agreement With Merck 47
Rules-Based Medicine Enters Into An Agreement With EMD Chemicals 48
Merck Signs Agreement With Archemix 49
Hutchison MediPharma Enters Into Research Collaboration With Merck 50
Glenmark Pharmaceutical Enters Into Agreement With Merck Generics 51
ChemGenex Pharmaceuticals Enters Into Agreement With Merck KgaA 52
Skinvisible Pharmaceuticals Enters Into Agreement With EMD Chemicals 53
Takeda Pharmaceutical Signs An Agreement With Merck 54
SkyePharma Amends Its Agreement With Merck 55
Merck Enters Into An Agreement With Jerini 56
Equity Offering 57
Merck Completes Rights Offering Of $2,659 Million 57
Merck Completes Rights Offering Of $699 Million 59
ImClone Systems Completes Private Placement Of $3.42 Million 61
ImClone Completes Private Placement Of $5 Million From Merck 62
Divestiture - Company 63
Mylan Laboratories Acquires Merck Generics From Merck 63
Biomet Acquires Biomet-Merck From Merck 64
Divestiture - Assets 65
Clinical Data Acquires Vilazodone Manufacturing Technology From Merck 65
Orgasynth Acquires Production Site From Merck 66
Debt Offering 67
Merck Completes Public Offering Of 4.875% Notes For $1,015.6 Million 67
Merck Completes Public Offering Of 4.75% Bonds For $725.7 Million 68
Merck Completes Private Placement Of Euro Benchmark Bond For $584 Million 69
Acquisition 70
Merck Specialities Acquires Bangalore Genei From Sanmar Group 70
Merck Acquires Bio-Fyt Pharma 71
Merck Acquires 73.99% Stake In PT Merck 72
Merck Acquires Serono 73
Merck Acquires Prasfarma From Almirall 74
Merck Acquires Survac 75
Key Competitors 76
Key Employees 76
Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Recent Developments 79
Strategy And Business Planning 79
Oct 22, 2009: EMD Seals Collaboration With MitoSciences 79
Oct 15, 2009: Merck Seals Agreement With Dyesol 79
Jul 15, 2009: Biowa Signs License Agreement With Merck 79
Jun 12, 2009: ImClone, Bristol-Myers Squibb Sign Agreement With Merck 80
Financial Announcements 80
Oct 26, 2009: Merck Revenues Increase by 2.7% to E1.9 Billion 80
Jul 23, 2009: Merck Posts Steady Revenues At E1902M 80
Government and Public Interest 81
Sep 30, 2009: Merck Submits NDA For Cladribine Tablets In US 81
Sep 17, 2009: Dey Settles State Of Utah Pricing Litigation 81
Jul 31, 2009: Merck Requests Re-examination Of CHMP Opinion For Erbitux 81
Product Approvals 82
Oct 15, 2004: FDA Approves Serono's (SRA) Luveris For Concomitant Use With Gonal-f 82
Clinical Trials 82
Jan 21, 2010: EMD Serono Announces Phase III Trial Results Of Cladribine Tablets 82
Dec 10, 2009: Oncothyreon Announces Merck KGaA's Initiation Of Phase 3 Trial Of Stimuvax For Advanced Non-Small Cell Lung Cancer 83
Jun 22, 2009: Oncothyreon Announces Initiation Of Phase III Trial Of Stimuvax In Breast Cancer 83
Jun 22, 2009: Oncothyreon Announces Initiation Of Phase III Trial Of Stimuvax In Breast Cancer 84
May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma 84
Nov 13, 2008: Clinical Data Show Long-Acting Human Growth Hormone ARX201 Is Safe And Well Tolerated 85
May 20, 2008: Tioga Pharmaceuticals’ Asimadoline Demonstrates Positive Results In A Phase 2b Clinical Trial For The Treatment Of Irritable Bowel Syndrome 85
Jun 23, 2006: Merck KGaA Announces Phase III Studies Of Sarizotan 85
Apr 28, 2006: Biomira Announces Final Phase 2B Survival Results Of Stimuvax (Formerly Known As BLP25 Liposome Vaccine) Trial In Patients With Non-Small Cell Lung Cancer 86
Nov 17, 2005: BLP25 Liposome Vaccine Phase 2 Study Interim Results Indicate No Safety Concerns With Reformulated Vaccine 86
May 16, 2005: Updated Survival Results From BLP25 Liposome Vaccine Phase IIb Study From Patients With Stage Iiib Non-Small Cell Lung Cancer (NSCLC) Presented 86
Dec 03, 2004: Merck KGaA Provides Update Of BLP25 Clinical Trial 87
Other Significant Developments 87
Oct 12, 2009: Merck To Unveil Parteck ODT In Spain 87
Sep 23, 2009: Initial COIN Study For Colorectal Cancer Fails To Meet Primary Endpoint 88
Sep 11, 2009: Merck Reports Results Of 40-Week IMPROVE Study 88
Sep 11, 2009: Merck Reports New Data From CLARITY Phase III Trial For Cladribine Tablets 89
Aug 01, 2009: Merck Presents Data For Combination Of Erbitux With Standard First-Line Therapy In NSCLC 89
Jul 23, 2009: Merck Submits MAA For Cladribine Tablets In Europe 89
Jul 16, 2009: Japanese Ministry of Health Approves Merck’s Gonal-f 90
Jul 16, 2009: Merck KgaA's Gonal-f Wins Japanese Approval For Ovulation Induction In Infertile Women 90
Jun 22, 2009: Merck KGaA Initiates Phase-III Study Of Stimuvax 90
Appendix 92
Methodology 92
About Global Markets Direct 92
Contact Us 92
Disclaimer 92
List of Tables
Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2008 1
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 12
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 12
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 13
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 13
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 14
Merck KGaA, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 14
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 15
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 15
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 16
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 16
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 17
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2004 to YTD 2010 17
Clayton, Dubilier & Rice Acquires VWR International 20
Merck Eprova Enters Into Licensing Agreement With Isofol Medical 21
King Pharmaceuticals Enters Into A Licensing Agreement With Merck Sante 22
BioWa Enters Into Licensing Agreement With Merck 23
PDS Biotechnology Enters Into Licensing Agreement With Merck Eprova 24
EMD Serono Enters Into An Agreement With Theratechnologies 25
Idera Pharmaceutical Enters Into Licensing Agreement With Merck 26
Merck Signs An Agreement With Sol-Gel Techologies 27
Merck Expands Licensing Agreement With Biomira 28
Merck Enters Into A Licensing Agreement With Abbott 29
Merck Enters Into An Agreement With Glenmark Pharmaceuticals 30
Dyax Enters Into Licensing Agreement With Serono 31
ImClone Systems Amends Development And License Agreement With Merck 32
Spectrum Pharmaceuticals Enters Into Licensing Agreement With Merck Eprova 33
Merck Expands Licensing Agreement With Biomira 34
Merck KGaA Enters Into License Agreement With Dyax 35
Merck Enters Into Licensing Agreement With Taiho Pharmaceutical 36
Merck Enters Into A Licensing Agreement With Organon BioSciences 37
Merck Enters Into Agreement With Peregrine 38
Eli Lilly Enters Into Licensing Agreement With Merck 39
Merck Enters Into An Agreement With Genaissance Pharmaceuticals 40
Cancer Research And Cancer Research Technology Enters Into An Agreement With Merck 41
EMD Serono Enters Into Collaboration Agreement With Brigham and Women’s Hospital 42
EMD Chemicals Enters Into Co-Development Agreement With MitoSciences 43
EMD Serono Enters Into Agreement With M. D. Anderson Cancer Center 44
Fast Forward Enters Into Worldwide Agreement With EMD Serono 45
EMD Serono Enters Into Co-Promotion Agreement With Emmaus Medical 46
caprotec bioanalytics Enters Into Collaboration Agreement With Merck 47
Rules-Based Medicine Enters Into An Agreement With EMD Chemicals 48
Merck Signs Agreement With Archemix 49
Hutchison MediPharma Enters Into Research Collaboration With Merck 50
Glenmark Pharmaceutical Enters Into Agreement With Merck Generics 51
ChemGenex Pharmaceuticals Enters Into Agreement With Merck KgaA 52
Skinvisible Pharmaceuticals Enters Into Agreement With EMD Chemicals 53
Takeda Pharmaceutical Signs An Agreement With Merck 54
SkyePharma Amends Its Agreement With Merck 55
Merck Enters Into An Agreement With Jerini 56
Merck Completes Rights Offering Of $2,659 Million 57
Merck Completes Rights Offering Of $699 Million 59
ImClone Systems Completes Private Placement Of $3.42 Million 61
ImClone Completes Private Placement Of $5 Million From Merck 62
Mylan Laboratories Acquires Merck Generics From Merck 63
Biomet Acquires Biomet-Merck From Merck 64
Clinical Data Acquires Vilazodone Manufacturing Technology From Merck 65
Orgasynth Acquires Production Site From Merck 66
Merck Completes Public Offering Of 4.875% Notes For $1,015.6 Million 67
Merck Completes Public Offering Of 4.75% Bonds For $725.7 Million 68
Merck Completes Private Placement Of Euro Benchmark Bond For $584 Million 69
Merck Specialities Acquires Bangalore Genei From Sanmar Group 70
Merck Acquires Bio-Fyt Pharma 71
Merck Acquires 73.99% Stake In PT Merck 72
Merck Acquires Serono 73
Merck Acquires Prasfarma From Almirall 74
Merck Acquires Survac 75
List of Figures
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals by Year, 2004 to YTD 2010 1
Merck KGaA, Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2004 to YTD 2010 1
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2004 to YTD 2010 7
Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2004 to YTD 2010 8
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2004 to YTD 2010 9
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2004 to YTD 2010 10
Merck KGaA, Pharmaceuticals & Healthcare, Medical Devices Deals, 2004 to YTD 2010 11